Loading market dashboard
Johnson & Johnson
JNJHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
When Tylenol pills were tampered with and tainted in 1982, Johnson & Johnson managed the setback in stride. More recently, the healthcare giant has been navigating legal issues related to talcum powder, which it once manufactured.
A Los Angeles jury on Friday sided with Johnson & Johnson in a lawsuit by the families of three women who alleged that the company's talc products caused ovarian cancer, finding that J&J was not negligent when selling cosmetic talc products.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Replacing $36,000 a year in income is roughly equivalent to generating the cash flow from a maximum Social Security benefit for a single retiree, or about $3,000 a month before taxes. A 66-year-old with $850,000 in a taxable brokerage account can build that income stream using five Dividend Aristocrats, relying on companies with decades-long records... Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street's consensus price targets, and four of the five just beat their most recent EPS estimates.
In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.
At the 24% federal bracket, a portfolio throwing off $40,000 in high-yield dividend income hands roughly $9,600 to the IRS every year when those shares sit in a taxable account treated as ordinary income. For investors in the gap years between retirement and RMD age 73, that drag compounds quietly until required minimum distributions force... How to Maximize Dividend Income in Retirement Before RMDs Change the Math
A combined household income of $110,000 is close to the national norm for a two-earner household. For a 56-year-old couple hoping to retire at age 60 and fund their lifestyle entirely through dividend income, that annual amount becomes the income target their portfolio must replace. The basic calculation is straightforward: divide the desired income by... Can Pure Dividend Stocks Replace a $110,000 Dual-Income Household Income? Here's What It Would Take
Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds Proceeds will support the conclusion of the STRIDE pivotal trial, continued operational scale-up, advancement of regulatory work toward a future Premarket Approval (PMA) submission to the FDA, and preparations for US commercialization Board strengthened with addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as Chair of the Audit Committee, and Tom Schnettler representing Series C investors BOSTON, June 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing of an $85 million Series C financing. Piper Sandler Merchant Banking led the financing with participation from Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic, along with existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what... This Is What a $1 Million Dividend Portfolio Pays After Taxes
Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2
Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg groupa The ongoing Phase 3 study of nipocalimab is currently recruiting people living with systemic lupus erythematosus – a debilitating autoantibody-driven disease which can lead to systemic organ damage LONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to demonstrate sustained reduction in disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE)a through 52 weeks in the Phase 2 JASMINE study as measured by both SRI-4b and Lupus Low Disease Activity State (LLDAS).c In addition, the study results showed greater response versus placebo plus background medicationd in participants who tested positive for lupus-associated autoantibodies, which represents the vast majority (~80%) of people living with SLE.e,1 These findings will be featured in a late-breaking presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London and are among the 38 abstracts the Company is presenting across its Rheumatology portfolio. Nipocalimab is designed to selectively block the neonatal Fc receptor (FcRn), reducing levels of circulating pathogenic immunoglobulin (IgG) autoantibodies and immune complexes associated with inflammation in SLE.2,3 By reducing circulating IgG, including autoantibodies, nipocalimab is designed to target the underlying cause of disease while preserving critical immune functions.4 JASMINE is the first clinical study to demonstrate efficacy of FcRn blockade in SLE and provides clinical, biomarker and pharmacodynamic evidence supporting the continued investigation of nipocalimab as a potential treatment option for this disease.5 A healthcare professional's perspective "The consistent improvements observed across established disease activity measures and reductions in pathogenic immunoglobulin G autoantibodies are encouraging and support the continued investigation of nipocalimab as a targeted treatment approach for people living with systemic lupus erythematosus," said Richard Furie, M.D.
Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren's disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and pain Nipocalimab is the only FcRn blocker granted both Breakthrough Therapy Designation and Fast Track Designation by the U.S. FDA for the treatment of adults with moderate-to-severe Sjögren's disease. LONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjögren's disease (SjD)a showing that participants with elevated autoantibody and immunoglobulin G (IgG) levelsb, who are often those who experience more substantial disease burden, showed greater clinical response rates.1 These data will be presented in an oral session at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress.
CNBC's Jim Cramer said investors should consider adding exposure to out-of-favor sectors if investors begin rotating away from high-flying technology stocks. He highlighted JPMorgan, Johnson & Johnson, Kimberly-Clark, McDonald's, Yum!
AbbVie's shareholders can sleep easy.
Persistent inflation is likely to keep the Federal Reserve from cutting rates until well into 2027.
The income target is straightforward: $12,500 a month equals $150,000 a year, and the portfolio doing the work is $2.8 million. Dividing the income by the capital gives the math the whole article has to solve: a blended yield of roughly 5.4%. That number falls in the middle of the income-investing spectrum, which is why... How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death 1
More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. Confirmed overall response rate was 42 percent, with more than one-third of responders achieving complete responses.
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized or locally advanced disease. The trial met both primary endpoints.
Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage trial presented on Sunday.
Generating $5,000 per month in passive income works out to $60,000 annually, a level many retirees target to cover core expenses without relying heavily on Social Security or selling assets during market downturns. At a 6% portfolio yield, reaching that income level requires roughly $1 million invested. The harder question is not simply reaching the yield... The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns
High energy prices have investors worried about a recession; these businesses should survive the hit just fine.
On May 29, 2026, Johnson and Johnson (JNJ) shares fell 2.4% to a current price of $225.33. Over the past 52 weeks, the stock has traded between a low of $149.04 a
Johnson & Johnson (JNJ) reached $225.33 at the closing of the latest trading day, reflecting a -2.37% change compared to its last close.
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations CHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypical epidermal growth factor receptor (EGFR) mutations. The analysis showed encouraging long-term outcomes with RYBREVANT® plus LAZCLUZE® in this difficult-to-treat population.
Passive income arrives on its own schedule, no effort required. Dividends keep landing in the brokerage account on a predictable schedule, regardless of headlines or market moves.
Building on the recent approval of Johnson & Johnson's TECVAYLI ® plus DARZALEX FASPRO® , MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI ® as early as second line TECVAYLI® delivered deep and durable responses with nearly two-thirds of patients achieving a complete response or better CHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with TECVAYLI® (teclistamab-cqyv) versus standard of care regimens in patients with relapsed or refractory multiple myeloma treated as early as second line. In a patient population whose myeloma was predominantly refractory to anti-CD38 therapy and lenalidomide, TECVAYLI® reduced the risk of disease progression or death by 71% and the risk of death by 40%.1 These data (Abstract #7507) will be presented as an oral session today at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, with simultaneous publication in The New England Journal of Medicine.
When choosing dividend ETFs, diversification is a top priority.
TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA).
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
Partnership strategy has produced great pharma bargains—and left the company exposed.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson'.
Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
Don't be too quick to give up on the industry.
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
A 50-year-old woman planning to retire at 70 on the equivalent of $80,000 in today's purchasing power is actually targeting a much larger nominal income figure. Assuming long-run inflation averages 3% annually, maintaining that same lifestyle 20 years from now would require roughly $144,500 per year in nominal dollars. That is the income her portfolio needs... Inflation Adjusted Dividend Income: How to Replace $80,000 in Today's Dollars 20 Years From Now
A $450,000 portfolio generating a 6% blended yield produces about $27,000 per year in income. For many early retirees between ages 55 and 65, that can function as a financial bridge between leaving full-time work and the arrival of Social Security and Medicare benefits. The underlying math is straightforward: $27,000 divided by a 6% yield... How $450,000 Can Deliver a $27,000 Paycheck Without Working a Day
Johnson & Johnson is a leader in the pharmaceutical and medical device markets. Consumers don't usually have many choices when it comes to their medical care.
A California retiree with a $1 million dividend portfolio earning a 5% blended yield grosses $50,000 in annual income.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance.
A 73-year-old retiree with a $1.2 million dividend portfolio generating $5,400 a month faces a quieter retirement problem than most. The income works, but it depends on corporations continuing to pay and raise dividends for another 20 to 25 years. Shifting $500,000 into a Single Premium Immediate Annuity (SPIA) replaces part of that market dependence... The Single Premium Immediate Annuity That Adds $3,800 a Month to a $1.2 Million Income Portfolio Without Touching a Stock
Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Dividend-growth blue chips like Coca-Cola double income in nine years despite lower starting yields, while high-yield BDCs and REITs with frozen payouts risk delivering less income over a decade than lower-yield growers.
The six names below sit firmly in the conservative-to-moderate tier. Five are Dividend Kings or Aristocrats.
In the latest trading session, Johnson & Johnson (JNJ) closed at $231.73, marking a +1.05% move from the previous day.
The U.S. median household income sits near $80,610, and a $1.1 million dividend portfolio generating a blended 7% yield would produce roughly $77,000 a year in cash flow. That level of income exceeds the median household income in most of the country, which helps explain why geography can dramatically change the retirement equation. The same... A Dividend Portfolio That Beats the Median Household Income in 47 of the 50 States on $1.1 Million Invested
The SPDR S&P Dividend ETF (NYSEARCA:SDY) is doing exactly what a yield-tilted dividend fund is supposed to do while the broader market wobbles: grinding higher while the broad market wobbles. SDY trades near $146, up 4% year to date after the S&P 500 finished Q1 2026 in negative territory. Over the past year, SDY has... If Treasury Yields Jump Above 4.75%, Here's What Happens to SDY
A single-family rental property in Toledo purchased for $135,000 at a 9% gross cap rate would generate roughly $12,150 annually in gross rental income. After accounting for property taxes, insurance, vacancies, maintenance, and property-management costs, the net cash flow may fall closer to $5,400 per year. To replace $400,000 annually with that level of net... A $400,000 Income Portfolio That Pays Like a Toledo Rental Property Without the 3 AM Phone Calls
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, launching a global program to develop an open surgical intelligence network— establishing Abu Dhabi as the first node in a global infrastructure designed to accelerate artificial intelligence (AI) innovation for every stage of the surgery experience. Integrating Johnson & Johnson's Polyphonic™ o.
